Advertisement

Pathogenic relevance of autoantibodies in dilated cardiomyopathy

  • Roland Jahns
  • Valérie Boivin
  • Georg Ertl
  • Martin J. Lohse
Part of the Progress in Inflammation Research book series (PIR)

Abstract

Dilated cardiomyopathy (DCM) is a heart muscle disease of unknown origin characterized by progressive cardiac dilatation and loss of contractile function in the absence of coronary artery disease. Genetic causes and cardiotoxic substances account for about one third of the cases, but the etiology of the two other thirds is still poorly understood. However, within the past two decades evidence has grown continuously that autoimmunity to certain cardiac antigens may play an important role in the development of DCM. Recent experiments in rodents even indicate that autoantibodies targeting the cardiac β1 (catecholamine) receptor can actually cause the disease. Dependent on the individual genetic predisposition, such harmful autoimmune reactions most likely occur as a result of heart muscle damage induced by viral triggers, ischemia, and/or exposure to cardiotoxins leading to myocyte apoptosis or necrosis, and subsequent liberation of self antigens previously hidden to the immune system. The following article reviews current evidence and recent experimental and clinical findings focusing on the possible role of autoantibodies against a confined number of cardiac self antigens in the pathogenesis of DCM.

Keywords

Dilate Cardiomyopathy Idiopathic Dilate Cardiomyopathy Cardiac Myosin Adenine Nucleotide Translocator Pathogenic Relevance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, Olsen I, Thiene G, Goodwin J, Gyarfas I et al (1996) Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Circulation 93: 841–842PubMedGoogle Scholar
  2. 2.
    American Heart Association (2007) Dallas; Heart disease and stroke statistics-2007 update. Circulation 115: e69–e171CrossRefGoogle Scholar
  3. 3.
    Morita H, Seidman J, Seidman CE (2005) Genetic causes of human heart failure. J Clin Invest 115: 518–526PubMedGoogle Scholar
  4. 4.
    Fabrizio L, Regan TJ (1994) Alcoholic cardiomyopathy. Cardiovasc Drugs Ther 8: 89–94CrossRefPubMedGoogle Scholar
  5. 5.
    Chien KR (2000) Myocyte survival pathways and cardiomyopathy: Implications for trastuzumab cardiotoxicity. Semin Oncol 27: 9–17PubMedGoogle Scholar
  6. 6.
    Freedman NJ, Lefkowitz RJ (2004) Anti-beta1-adrenergic receptor antibodies and heart failure: Causation, not just correlation. J Clin Invest 113: 1379–1382PubMedGoogle Scholar
  7. 7.
    Jahns R, Boivin V, Lohse MJ (2006) Beta1-adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy. Trends Cardiovasc Med 16: 20–24CrossRefPubMedGoogle Scholar
  8. 8.
    Kühl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, Schultheiss HP (2005) Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 112: 1965–1970CrossRefPubMedGoogle Scholar
  9. 9.
    Limas CJ (1997) Cardiac autoantibodies in dilated cardiomyopathy. Circulation 95: 1979–1980PubMedGoogle Scholar
  10. 10.
    Luppi P, Rudert WA, Zanone MM, Stassi G, Trucco G, Finegold D, Boyle GJ, Del Nido P, McGowan FX, Trucco M (1998) Idiopathic dilated cardiomyopathy. A superantigendriven autoimmune disease. Circulation 98: 777–785PubMedGoogle Scholar
  11. 11.
    Mahrholdt H, Wagner A, Deluggi CC, Kispert E, Hager S, Meinhardt G, Vogelsberg H, Fritz P, Dippon J, Bock C-T et al (2006) Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 114: 1581–1590CrossRefPubMedGoogle Scholar
  12. 12.
    MacLellan WR, Lusis AJ (2003) Dilated cardiomyopathy: Learning to live with yourself. Nat Med 9: 1455–1456CrossRefPubMedGoogle Scholar
  13. 13.
    Smulski C, Labovsky V, Levy G, Hontebeyrie M, Hoebeke J, Levin MJ (2006) Structural basis of the cross-reaction between an antibody to the Trypanosoma cruzi ribosomal P2beta protein and the human beta1-adrenergic receptor. FASEB J 20: 1396–1406CrossRefPubMedGoogle Scholar
  14. 14.
    Maekawa Y, Ouzounian M, Opavsky MA, Liu PP (2007) Connecting the missing link between dilated cardiomyopathy and viral myocarditis. Circulation 115: 5–8CrossRefPubMedGoogle Scholar
  15. 15.
    Schultheiss HP, Bolte HD (1985) Immunological analysis of autoantibodies against the adenine nucleotide translocator in dilated cardiomyopathy. J Mol Cell Cardiol 17: 603–617CrossRefPubMedGoogle Scholar
  16. 16.
    Schultheiss HP, Kühl U, Janda I, Melzner B, Ulrich G, Morad M (1988) Antibodymediated enhancement of calcium permeability in cardiac myocytes. J Exp Med 168: 2102–2109CrossRefGoogle Scholar
  17. 17.
    Schulze K, Witzenbichler B, Christmann C, Schultheiss HP (1999) Disturbance of myocardial energy metabolism in experimental virus myocarditis by antibodies against the adenine nucleotide translocator. Cardiovasc Res 44: 91–100CrossRefPubMedGoogle Scholar
  18. 18.
    Pohlner K, Portig I, Pankuweit S, Lottspeich F, Maisch B (1997) Identification of mitochondrial antigens recognized by the antibody in sera of patients with dilated cardiomyopathy by two-dimensional gel electrophoresis and protein sequencing. Am J Cardiol 80: 1040–1045CrossRefPubMedGoogle Scholar
  19. 19.
    Neumann DA, Burek CL, Baughman KL, Rose NR, Herskowitz A (1990) Circulating heart-reactive antibodies in patients with myocarditis or cardiomyopathy. J Am Coll Cardiol 16: 839–846CrossRefPubMedGoogle Scholar
  20. 20.
    Caforio AL, Mahon NJ, Tona F, McKenna WJ (2002) Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: Pathogenetic and clinical significance. Eur J Heart Fail 4: 411–417CrossRefPubMedGoogle Scholar
  21. 21.
    Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N et al (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9: 1477–1483CrossRefPubMedGoogle Scholar
  22. 22.
    Göser S, Andrassy M, Buss SJ, Leuschner F, Volz CH, Öttl R, Zittrich S, Blaudeck N, Hardt SE, Pfitzer G et al (2006) Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation 114: 1693–1702CrossRefPubMedGoogle Scholar
  23. 23.
    Li Y, Heuser JS, Cunningham LC, Kosanke SD, Cunningham MW (2006) Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol 177: 8234–8240PubMedGoogle Scholar
  24. 24.
    Magnusson Y, Wallukat G, Waagstein F, Hjalmarson Å, Hoebeke J (1994) Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta1-adrenoceptor with positive chronotropic effect. Circulation 89: 2760–2767PubMedGoogle Scholar
  25. 25.
    Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F (1999) Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 99: 649–654PubMedGoogle Scholar
  26. 26.
    Christ T, Schindelhauer S, Wettwer E, Wallukat G, Ravens U (2006) Interaction between autoantibodies against the beta1-adrenoceptor and isoprenaline in enhancing L-type Ca2+ current in rat ventricular myocytes. J Mol Cell Cardiol 41: 716–723CrossRefPubMedGoogle Scholar
  27. 27.
    Fu LXM, Magnusson Y, Bergh CH, Waagstein F, Hjalmarson Å, Hoebeke J (1993) Localization of a functional autoimmune epitope on the second extracellular loop of the human muscarinic acetylcholine receptor 2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 91: 1964–1968CrossRefPubMedGoogle Scholar
  28. 28.
    Limas CJ (1996) Autoimmunity in dilated cardiomyopathy and the major histocompatibility complex. Int J Cardiol 54: 113–116CrossRefPubMedGoogle Scholar
  29. 29.
    Limas CJ, Iakovis P, Anyfantakis A, Kroupis C, Cokkinos DV (2004) Familial clustering of autoimmune diseases in patients with dilated cardiomyopathy. Am J Cardiol 93: 1189–1191CrossRefPubMedGoogle Scholar
  30. 30.
    Hoebeke J (1996) Structural basis of autoimmunity against G protein-coupled membrane receptors. Int J Cardiol 54: 103–111CrossRefPubMedGoogle Scholar
  31. 31.
    Mobini R, Maschke H, Waagstein F (2004) New insights into the pathogenesis of dilated cardiomyopathy: Possible underlying mechanisms and therapy. Autoimmun Rev 3: 277–284CrossRefPubMedGoogle Scholar
  32. 32.
    Elies R, Ferrari I, Wallukat G, Lebesgue D, Chiale P, Elizari M, Rosenbaum M, Hoebeke J, Levin MJ (1996) Structural and functional analysis of the B cell epitopes recognized by anti-receptor autoantibodies in patients with Chagas’ disease. J Immunol 157: 4203–4211PubMedGoogle Scholar
  33. 33.
    Ferrari I, Levin M, Wallukat G, Elies R, Lebesgue D, Chiale P, Elizari M, Rosenbaum M, Hoebeke J (1995) Molecular mimicry between the immunodominant ribosomal protein PO of Trypanosoma cruzi and a functional epitope on the human beta1-adrenergic receptor. J Exp Med 182: 59–65CrossRefPubMedGoogle Scholar
  34. 34.
    Wallukat G, Wollenberger A, Morwinski R, Pitschner HF (1995) Anti-beta1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: Mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol 27: 397–406CrossRefPubMedGoogle Scholar
  35. 35.
    Magnusson Y, Hjalmarson Å, Hoebeke J (1996) Beta1-adrenoceptor autoimmunity in cardiomyopathy. Int J Cardiol 54: 137–141CrossRefPubMedGoogle Scholar
  36. 36.
    Bachmaier K, Neu N, de la Maza LM, Pal S, Hessel A, Penninger JM (1999) Chlamydia infections and heart disease linked through antigenic mimicry. Science 283: 1335–1339CrossRefPubMedGoogle Scholar
  37. 37.
    Rose NR (2001) Infection, mimics, and autoimmune disease. J Clin Invest 107: 943–944CrossRefPubMedGoogle Scholar
  38. 38.
    Eriksson U, Ricci R, Hunziker L, Kurrer MO, Oudit GY, Watts TH, Sonderegger I, Bachmaier K, Kopf M, Penninger JM (2003) Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 9: 1484–1490CrossRefPubMedGoogle Scholar
  39. 39.
    Witebsky E, Rose NR, Terplan K, Paine JR, Egan RW (1957) Chronic thyreoiditis and autoimmunization. J Am Med Assoc 164: 1439–1447PubMedGoogle Scholar
  40. 40.
    Rose NR, Bona C (1993) Defining criteria for autoimmune diseases (Witebsky’s postulates revisited). Immunol Today 14: 426–430CrossRefPubMedGoogle Scholar
  41. 41.
    Portig I, Pankuweit S, Maisch B (1997) Antibodies against stress proteins in sera of patients with dilated cardiomyopathy. J Mol Cell Cardiol 29: 2245–2251CrossRefPubMedGoogle Scholar
  42. 42.
    Okazaki T, Honjo T (2005) Pathogenic roles of cardiac autoantibodies in dilated cardiomyopathy. Trends Mol Med 11: 322–326CrossRefPubMedGoogle Scholar
  43. 43.
    Liu B, Dai J, Zheng H, Stoilova D, Sun S, Li Z (2003) Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc Natl Acad Sci USA 100: 15824–15829CrossRefPubMedGoogle Scholar
  44. 44.
    Reichlin M (1998) Cellular dysfunction induced by penetration of autoantibodies into living cells: Cellular damage and dysfunction mediated by antibodies to dsDNA and ribosomal P protein. J Autoimmun 11: 557–561CrossRefPubMedGoogle Scholar
  45. 45.
    Schulze K, Becker BF, Schauer R, Schultheiss HP (1990) Antibodies to ADP-ATP carrier — an autoantigen in myocarditis and dilated cardiomyopathy-impair cardiac function. Circulation 81: 959–969PubMedGoogle Scholar
  46. 46.
    Khoynezhad A (2007) Promising aspects and caveats of studies on anti-apoptotic therapies in patients with heart failure. Eur J Heart Fail 9: 120–123CrossRefPubMedGoogle Scholar
  47. 47.
    Nishimura H, Okazaki T, Tanaka Y, Natakani K, Hara M, Matsumori A et al (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291: 319–322CrossRefPubMedGoogle Scholar
  48. 48.
    Caforio AL, Grazzini M, Mann JM, Keeling PJ, Botazzo GF, McKenna WJ, Schiaffino S (1992) Identification of a-and b-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 85: 1734–1742PubMedGoogle Scholar
  49. 49.
    Lauer B, Schannwell M, Kühl U, Strauer BE, Schultheiss HP (2001) Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 35: 11–18CrossRefGoogle Scholar
  50. 50.
    Neu N, Ploier B, Öfner C (1990) Cardiac myosin-induced myocarditis: Heart autoantibodies are not involved in the induction of the disease. J Immunol 145: 4094–4100PubMedGoogle Scholar
  51. 51.
    Lohse MJ, Engelhardt S, Eschenhagen T (2003) What is the role of beta-adrenergic signaling in heart failure? Circ Res 93: 896–906CrossRefPubMedGoogle Scholar
  52. 52.
    Matsui S, Fu M, Shimizu M, Fukuoka T, Teraoka K, Takekoshi N, Murakami E, Hjalmarson A (1995) Dilated cardiomyopathy defines serum autoantibodies against G protein-coupled cardiovascular receptors. Autoimmunity 21: 85–88CrossRefPubMedGoogle Scholar
  53. 53.
    Wang WZ, Zhao RR, Wu BW, Jin XH, Zuh L, Hjalmarson A, Fu LXM (1996) Effects of anti-peptide antibodies against human M2 muscarinic receptors on cardiac function of rats in vivo. Blood Press Suppl 3: 25–27Google Scholar
  54. 54.
    Baba A, Yoshikawa T, Fukuda Y, Sugiyama T, Shimada M, Akaishi M, Tsuchimoto K, Ogawa S, Fu M (2004) Autoantibodies against M2-muscarinic acetylcholine receptors: New upstream targets in atrial fibrillation in patients with dilated cardiomyopathy. Eur Heart J 25: 1108–1115CrossRefPubMedGoogle Scholar
  55. 55.
    Iwata M, Yoshikawa T, Baba A, Anzai T, Mitamura H, Ogawa S (2001) Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 37: 418–424CrossRefPubMedGoogle Scholar
  56. 56.
    Christ T, Wettwer E, Dobrev D, Adolph E, Knaut M, Wallukat G, Ravens U (2001) Autoantibodies against the beta1-adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol 33: 1515–1525CrossRefPubMedGoogle Scholar
  57. 57.
    Iwata M, Yoshikawa T, Baba A, Anzai T, Nakamura I, Wainai Y, Takahashi T, Ogawa S (2001) Autoimmunity against the second extracellular loop of beta1-adrenergic receptors induces beta-adrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ Res 88: 578–586PubMedGoogle Scholar
  58. 58.
    Jahns R, Siegmund C, Jahns V, Reiländer H, Maidhof A, Müller-Esterl W, Lohse MJ, Boege F (1996) Probing human beta1-and beta2-adrenoceptors with domain-specific fusion protein antibodies. Eur J Pharmacol 316: 111–121CrossRefPubMedGoogle Scholar
  59. 59.
    Jahns R, Boivin V, Krapf T, Wallukat G, Boege F, Lohse MJ (2000) Modulation of beta1-adrenoceptor activity by domain-specific antibodies and heart failure-associated autoantibodies. J Am Coll Cardiol 36: 1280–1287CrossRefPubMedGoogle Scholar
  60. 60.
    Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, Lohse MJ (2004) Direct evidence for a beta1-adrenergic receptor directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 113: 1419–1429PubMedGoogle Scholar
  61. 61.
    Engelhardt S, Hein L, Wiesmann F, Lohse MJ (1999) Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96: 7059–7064CrossRefPubMedGoogle Scholar
  62. 62.
    Woodiwiss AJ, Tsotetsi OJ, Sprott S, Lancaster EJ, Mela T, Chung ES, Meyer TE, Norton GR (2001) Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. Circulation 103: 155–160PubMedGoogle Scholar
  63. 63.
    Hershko AY, Naparstek Y (2005) Removal of pathogenic autoantibodies by immunoadsorption. Ann NY Acad Sci 1051: 635–646CrossRefPubMedGoogle Scholar
  64. 64.
    Jahns R, Boivin V, Siegmund C, Boege F, Lohse MJ, Inselmann G (1999) Activating beta1-adrenoceptor antibodies are not associated with cardiomyopathies secondary to valvular or hypertensive heart disease. J Am Coll Cardiol 34: 1545–1551CrossRefPubMedGoogle Scholar
  65. 65.
    Limas CJ, Goldenberg IF, Limas C (1992) Assessment of immune modulation of betaadrenergic pathways in human dilated cardiomyopathy: Influence of methodologic factors. Am Heart J 123: 967–970CrossRefPubMedGoogle Scholar
  66. 66.
    Nikolaev VO, Boivin V, Stoerk S, Angermann CE, Ertl G, Lohse MJ, Jahns R (2007) A novel fluorescent method for the rapid detection of functional beta1-adrenergic receptor autoantibodies in heart failure. J Am Coll Cardiol 50: 423–31CrossRefPubMedGoogle Scholar
  67. 67.
    Chiale PA, Ferrari I, Mahler E, Vallazza MA, Elizari MV, Rosenbaum MB, Levin MJ (2001) Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus node dysfunction. Circulation 103: 1765–1771PubMedGoogle Scholar
  68. 68.
    Störk S, Boivin V, Horf R, Hein L, Lohse MJ, Angermann CE, Jahns R (2006) Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J 152: 697–704CrossRefPubMedGoogle Scholar
  69. 69.
    Wallukat G, Müller J, Hetzer R (2002) Specific removal of beta1-adrenergic antibodies directed against cardiac proteins from patients with idiopathic dilated cardiomyopathy. N Engl J Med 347: 1806CrossRefPubMedGoogle Scholar
  70. 70.
    Anderton SM (2001) Peptide-based immunotherapy of autoimmunity: A path of puzzles, paradoxes, and possibilities. Immunology 104: 367–376CrossRefPubMedGoogle Scholar
  71. 71.
    Mobini R, Staudt A, Felix SB, Baumann G, Wallukat G, Deinum J, Hjalmarson Å, Fu M (2003) Hemodynamic improvement and removal of autoantibodies against beta1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmunity 20: 345–350CrossRefGoogle Scholar

Copyright information

© Springer Basel 2010

Authors and Affiliations

  • Roland Jahns
    • 1
    • 2
  • Valérie Boivin
    • 2
  • Georg Ertl
    • 1
  • Martin J. Lohse
    • 2
  1. 1.Department of Internal Medicine, Medizinische Klinik und Poliklinik I, CardiologyUniversity Hospital of WürzburgWürzburg
  2. 2.Institute of Pharmacology and ToxicologyUniversity of WürzburgWürzburgGermany

Personalised recommendations